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Abstract
Thyroid associated orbitopathy is a common manifestation of Graves disease. Many options can be considered for
treatment. In this case series, we reviewed the medical records of 17 patients who received radiation therapy (RT)
for GO in a tertiary care center between 1997 and 2007. All patients received 20 Gy to both orbits and 12 of them
(71%) had already received one or more trials of steroid therapy prior to RT. After a median follow-up of 2 years, a
subjective improvement in exophthalmos and vision was reported by all patients at the end of RT but only 3
patients reported a decrease in their diplopia immediately after therapy. Symptoms continued to improve with
time in many patients: 22% had complete reversal of their symptoms and signs, and the remaining 78% had partial
improvement. Two patients developed recurrent signs and symptoms, both of them were smokers who continued
to smoke after treatment. About 60-65% of patients responded favorably to RT alone which increased to 87-97%
when RT is combined with steroids. No patients developed late toxicity during the follow-up period. We conclude
that RT is an effective treatment option in GO even in patients who failed previous treatment with steroids or
surgical decompression. Based on our own clinical experiences and the literature data, the combination of RT and
intravenous corticosteroid administration may improve the response rate.
Introduction
Thyroid associated orbitopathy [TAO], is the most com-
mon extrathyroidal manifestation of Graves disease, and
continues to be a dilemma with regard to its pathogen-
esis and its therapy.
Clinically evident ophthalmopathy occurs in 10% to
25% of patients with Graves thyrotoxicosis. This preva-
lence may increase up to 45% if eyelid changes are
included, and eye involvement detected by computed
tomography (CT) are considered [1,2]. Glucocorticoids
have been used for the treatment of TAO for more
than 40 years [3] but their effect in decreasing propto-
sis and improving ocular motility has not always been
impressive and ranges between 40 and 80% [4-6]. On
the other hand, orbital radiotherapy has been used for
treatment of TAO for more than sixty years, and this
treatment methodology has become widely used over
the last years, in view of its nonspecific antiinflamma-
tory effect and the high radiosensitivity of lymphocytes
infiltrating the orbital space [7]. However, the precise
therapeutic target in the treatment of radiotherapy in
TAO is still not well understood. It remains unclear
whether lymphocytes, mesenchymal cells or the combi-
nation of both are the target tissue. Clinical studies
have shown that the effects of orbital irradiation may
take several weeks to become manifest but are more
prolonged than those of glucocorticoids. Although
TAO can sometimes be controlled in the long term
with orbital irradiation alone [8], the reduction in
proptosis and the improvement in ocular motility, are
not impressive [9].
To our knowledge, the effect of RT on TAO has not
been assessed in the Middle East region. In this retro-
spective study, we reviewed the charts of patients who
were treated for TAO with radiation therapy at our ter-
tiary care center in the Middle East between 1997 and
2007. Seventeen patients were available for this study.
Baseline characteristics of the patients, their presenting
symptoms, biochemical data, additional treatment and
outcome data after radiation therapy were collected.
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Our research was in compliance with the Helsinki
Declaration and approval was obtained from the IRB
committee at our institution. All patients gave their
informed consent to partake in the project. Seventeen
patients (8 men and 9 women) were identified during
the study period (Table 1). The median age was 50
years (28-67) in men and 49 years (20-56) in women.
The majority had the onset of hyperthyroidism before
GO (72%), whereas GO was the presenting manifesta-
tion in four patients only. The median interval between
the onset of hyperthyroidism and the onset of GO was 6
months (0-120). The median TSH, free T3 and free T4
before starting radiotherapy were 0.16 μU/ml, 2.5 ng/dl
and 1.5 ng/dl respectively. Four patients were hyperthyr-
oid and 13 were euthyroid. The median duration of GO
prior to receiving RT was 16 months (1 month-8 years).
Twelve patients received radioactive iodine (RAI) at a
median interval of 42 months (24-216) before develop-
ing GO. Only 1 patient received RAI after developing
GO. Twelve patients were smokers. All patients had
proptosis. Palpebral edema was present in 10 patients
(59%) and ophthalmoplegia in 11 (65%). Symptoms were
bilateral in two thirds of affected patients and unilateral
in one third of them.
All 17 patients were treated by orbital radiation, with
concurrent steroids (except in one patient) mainly con-
sisting of high dose intravenous methylprednisolone (1
g/day for 5 days). Twelve patients (71%) had also
received one or several courses of steroids prior to RT
with variable regimen ranging from 1 mg/kg/day of oral
prednisone with gradual tapering, to 1 mg/day of IV
methylprednisolone over 5 days. Three patients had
undergone bilateral surgical orbital decompression at an
interval of 2 months to 1 year prior to RT but they
were referred for radiation therapy because of persis-
tence of their symptoms, consisting mainly of
exophthalmos and poor vision. All patients received a
dose of 20 Gy to both eyes fractionated in 10 daily
doses over a 2-week period. Treatment was delivered
thru parallel opposed 6MV beams using a downward 5°
tilt to avoid direct irradiation to the contralateral lens.
The treated volume consisted of the entire orbital con-
tent from the orbital apex posteriorly to the fleshy can-
tus anteriorly. Patients were followed at regular interval
by their endocrinologist and opthtalmologist. Subjective
assessment of diplopia and exophthalmos were per-
formed at baseline, at the end of radiotherapy and at the
last visit. Evaluation immediately after radiation therapy
is available for all patients but long term follow-up is
available for only 9 patients. Median follow-up time was
two years.
Results
Immediate response
Sixteen patients (94.1%) described subjective
improvement in their vision and a decrease in the
exophthalmos at the end of RT. Eight patients (47%)
had no change in their diplopia the last day of RT
and 3 reported some improvement. These outcomes
are detailed in Table 2. In terms of acute toxicity,
two patients developed bilateral eye redness toward
the end of RT.
Table 1 Baseline characteristics of the study population
Characteristic Number (Percentage %)
Gender
Male 8 (47)
Female 9 (53)
Age* (years) 50 (20-67)
Hyperthyroidism
Yes 16 (94.1)
No 1 (5.9)
Smoking
Current 10 (71.4)
Ex 2 (14.3)
No 2 (14.3)
Prior Radioactive Iodine
Yes 13 (76.5)
No 4 (23.5)
Prior steroid therapy
Yes 12 (70.6)
No 5 (29.4)
Prior Surgery
Yes 3 (17.6)
No 14 (82.4)
Interval between 6 [0-120]
hyperthyroidism and
Ophtalmopathy* (months)
Interval between 68 [24-216]
Radioiodine and Radiation
Therapy* (months)
*Values are Median [min-max]
Table 2 Outcome of radiation therapy
Outcome Number (Percentage)
Overall outcome
Stable 1 (5.9%)
Improved 16 (94.1%)
Diplopia
Stable 8 (72.7%)
Improved 3 (27.3%)
Exophtalmos
Stable 1 (5.9%)
Improved 16 (94.1%)
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Data on long term effect are available for 9 patients
(53%). 2 among them (22%) had complete reversal of
their diplopia and exophthalmos which were maintained
up to 3 year follow-up, whereas 7 among them (78%)
had partial response only in exophthalmos, diplopia or
both. These 7 cases are detailed as follows:
- Residual minimal diplopia involving vertical gaze
only persisted in one patient after six months, and
in another patient 4 years after the end of RT.
- One patient had minimal response in her
exophthalmos after 2 months of follow-up but she
was later lost to follow up and further assessment
was not available.
- Another patient had residual minimal exophthal-
mos after 2 years of follow-up.
- One patient had good results initially but her
exophthalmos was still cosmetically unacceptable to
her and underwent debulking orbital surgery one
year after RT.
- The remaining two women experienced recurrence
of their symptoms, both of them were smokers who
did not quit smoking after RT. The first patient
developed recurrence of diplopia and exophthalmos
5 months after RT. Her diplopia, but not the
exophthalmos responded well to pulse steroids. The
other patient developed bilateral eyelid swelling and
hyperemia but without diplopia, two years following
RT, and responded well to oral prednisone.
Discussion
TAO is considered an autoimmune disorder and like
many autoimmune diseases, it is more prevalent in
w o m e nt h a ni nm e n[ 8 ] .T h ep r e v a l e n c eo fG Oi sf i v e
times higher in women than in men [10]. The distribu-
tion is bimodal, with peak incidence in the age groups
40 to 44 years and 60 to 64 years in women and 45 to
49 years and 65 to 69 years in men. Thus, the median
age in our study (49 and 50 years) reflects the general
age prevalence. In our study, females were slightly more
frequent than males. However, this does not reflect the
true female to male ratio in our population, since we
only included those referred for radiation therapy.
Many classification systems have been used for TAO
including the NOSPECS classification of eye changes of
Graves’ disease: [N stands for No signs or symptoms; O,
only signs, no symptoms; S, soft tissue involvement; P,
proptosis; E, extraocular muscle involvement; C, corneal
involvement; S, sight loss (due to optic nerve involve-
ment)]. Information regarding antithyroid antibodies
were lacking in our series. However, there is no estab-
lished correlation between serum levels of antithyroid
antibodies and severity of ophthalmopathy, although it
has been reported that severe ophthalmopathy tends to
develop in the presence of high titers in the serum
antithyroid-stimulating antibody [11-13]. Once a patient
has Graves disease, the major clinical risk factor for
developing thyroid eye disease is smoking [10]. A MED-
LINE search identified 25 studies on the association
between smoking and thyroid diseases and found that
patients with thyroid eye disease are four times more
likely to be smokers or former smokers than never smo-
kers [14]. The detrimental effect of smoking to the orbi-
tal immune process is mediated by modulating the
release of autoantigens from the thyroid, inducing local
hypoxia which increases glycosaminoglycan production
by fibroblasts [15], and by modulating the secretion of
cytokines and cytokine antagonists such as the IL-1
receptor antagonist [16]. The response rate to treatment
modalities including steroids and retrobulbar irradiation
is better in non smokers compared to smokers [17].
Moreover, smoking cessation might have a beneficial
effect on GO even when the disease is already present.
The role of smoking as an exacerbating factor was
shown in our case series where 84% of patients have
been exposed to tobacco smoking the majority being
current smokers at the time of diagnosis and the two
patients who continued to smoke after RT developed
recurrence of their symptoms.
Five patients have already received radio-active-iodine
at the time of RT, at an interval of 2 to 18 years before
RT. Whereas antithyroid drugs or thyroid surgery do
not seem to alter the natural course of Graves ophthal-
mopathy,
131I therapy carries a small risk for develop-
ment or worsening of eye changes, which fortunately
are mostly transient in nature [18,19]. This adverse
effect of
131I therapy is particularly apparent in patients
who smoke, who have a pretreatment serum triiodothyr-
onine of > 5 nmol/l, high levels of serum anti-thyrotro-
pin receptor antibodies, and the presence of ocular signs
or symptoms [20]. Cigarette smoking was also shown to
increase the risk of progression of ophthalmopathy after
radioiodine therapy [21].
All our patients received a dose of 20 Gy to both eyes
fractionated in 10 daily doses over a 2-week period.
Orbital radiotherapy was utilized for many years for the
treatment of Graves ophthalmopathy [7]. Nowadays,
most centers use linear accelerators delivering 4-6
megavolts and a 4 × 4-cm lateral field slightly angled
posteriorly to avoid as much as possible irradiation to
the contralateral lens. The most common delivered dose
is 20 Gy [7]. A lower dose of 10 Gy was found to be
equally effective in some but not all studies [6,22,23],
and the use of higher cumulative doses of radiation does
not provide further benefit [23-25]. Thus, at present the
dose of 20 Gy is considered the optimal dose for orbital
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daily doses over a 2-week period to reduce the catarac-
togenic effect of irradiation [26]. Recently, Kahaly et al.
[25] showed that 1 Gy/week protocol was better toler-
ated than the classical 2-week scheme but the longer
treatment duration makes this protocol less practical.
Orbital radiotherapy, when properly performed, is
usually well tolerated. It may be associated with a transi-
ent exacerbation of inflammatory eye signs and symp-
toms [27] which can be attenuated by steroids [28]. The
reported side effects of radiotherapy include cataracts
(12% incidence after a median 11 years, radiation retino-
pathy and second malignancy (calculated risk of 1.2%
[29]). In our study, none of the patients developed any
of the known adverse events; keeping in mind that long-
term follow-up is available only for nine patients. The
major concern of physicians and the patients relates to
the possibility that orbital radiotherapy may be carcino-
genic. No second cancer has been detected yet in our
small patient population.
In our series, almost all patients had good outcome
immediately after RT. A number of retrospective studies
have reported the efficacy of orbital irradiation [30-33].
Most of them noted improvement in soft tissue inflamma-
tion but less improvement in motility or amount of prop-
tosis. Donaldson et al. [27] who were the first to use a 4-
6MV linear accelerator in a group of 23 patients with
severe GO reported good response in 65% of cases, includ-
ing those who had previously poor response to systemic
glucocorticoid treatment. Marcocci [34] summarized the
results of 25 publications on radiation for GO and noted
that on average, 60% of patients responded favorably to
radiation. Prospective studies were also conducted to test
the efficacy of radiation in treating GO. Wiersinga et al.
[35] reported improvement at 6 months in 64% of patients
who received 20 Gy after achieving poor response to ster-
oids or in whom steroids were contraindicated. In another
prospective trial [29], patients were randomized to radia-
tion or sham treatment. Improvement was observed in
60% of the radiation group compared with 31% in the
sham group. Improvements were seen only in motility
(degree of diplopia), but not in soft tissue swelling, which
is in contrast to the findings noted in most retrospective
series [6]. In our study, 12 patients (71%) received steroids
prior to RT and 94% had concurrent steroids with RT
with high IV doses. Although radiation provides long-term
benefits and a more sustained action for the treatment of
GO [21,36], it might take several weeks to show its effects,
while corticosteroid pulse therapy produces short-term
benefits because of its rapid action. The response rate to
steroids in thyroid eye disease varies from 33% to 77%
[37-39]. The soft-tissue changes, consisting of edema of
the conjunctiva, eyelids, and periorbital area, show the
most marked improvement with steroids while the
r e d u c t i o ni np r o p t o s i sa n dt h ei m p r o v e m e n ti no c u l a r
motility are usually less impressive [9]. Some evidence sug-
gests that short-term high doses of intravenous steroids
are better tolerated by patients and may improve outcome
in patients undergoing radiation compared with patients
undergoing slow tapering of prednisone [40]. Sustained
improvement in visual acuity, eye muscle motility, propto-
sis, and rectus muscle thickness have also been reported
t ob e t t e rr e s p o n dt oI Vt h e r a p y .T h i si st h er e a s o nw h y
the great majority of our patients received high doses of
IV steroids during RT. In a study by Bartalena et al [28],
patients were randomly assigned to combined therapy
with orbital cobalt irradiation and systemic methylpredni-
solone or to systemic methylprednisolone alone. The
treatment responses were less satisfactory with methyl-
prednisolone group compared to the other group. The
findings were in accordance with other randomized pro-
spective studies showing that orbital radiotherapy com-
bined with high-dose oral glucocorticoids was more
effective in reducing soft tissue changes and ocular moti-
lity than orbital radiotherapy alone [41,42]. In contrast,
another nonrandomized clinical trial [43] showed that
high-dose IV methylprednisolone pulse therapy alone was
as effective as high-dose IV methylprednisolone pulse
therapy followed by orbital radiotherapy in reducing mus-
cle hypertrophy in Japanese patients with GO. However,
no beneficial therapeutic effect on proptosis was observed
in that study in either group at 1 month and 6 months of
treatment.
Conclusion
In this retrospective study, we were able to show that
combined therapy with RT and high dose steroids is a
good option for patients with TAO even in those who
have already failed previous treatment with steroids
alone or decompression surgery. This treatment modal-
ity is well tolerated and long-term complications are
almost nonexisting.
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